ArticleEye (London, England)2025

Response to 'Comment on: 'Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity".

Puja Maitra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.